The FDA’s Oncology Drugs Advisory Committee recognized that Imfinzi met its primary endpoint of event-free survival in the treatment of resectable non-small cell lung cancer.
Imfinzi plus pre-operative chemotherapy shows significant benefit in event-free survival in the treatment of resectable non-small cell lung cancer
Leave a comment
